Complimentary medication therapy is vastly used in the treatment of cancer. It is used in the standard treatment of cancer. In Medicare, there are ethnic, cultural or genetics differences in the use and consideration for cancer treatment. Some evidence shows there are ethnic disparities in treatment, metabolism, clinical effectiveness and pain related condition such that, the experience in pain differently activate the stress-related response from the body physiologically across various group ethnically. Members from the same ethnicity use similar pain management strategies. Thus over the year pain perception have been documented showing that Africa-Americans and other minorities experience greater suffering and pain while compared to whites in many reports of multidisciplinary pain centres.

Culture in pharma-therapy is evidence when local prefer a given health care providers and they have some over-valuation on given medical condition or ignore others. It goes in hand with the ethnic drug to drug interaction where at the time a drug is approved in one country and not around in another country (Lupton, 2012). Cancer pharmacogenomics studies have shown that genetic ancestry research tends to be self-determined in relation to the race on chemotherapies.